Is antidepressant treatment associated with reduced cognitive decline in Alzheimer's disease?

Dementia and Geriatric Cognitive Disorders

Volumn 25, Issue 4, 2008, Pages 372-379

  Mossello, Enrico ^a,d   Boncinelli, Marta ^a   Caleri, Veronica ^b   Cavallini, Maria Chiara ^a   Palermo, Eliana ^a   Di Bari, Mauro ^a   Tilli, Sabrina ^a   Sarcone, Eva ^a   Simoni, David ^a   Biagini, Carlo Adriano ^b   Masotti, Giulio ^a,c   Marchionni, Niccolò ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Azienda USL 3   (Italy)

^c Foundation 'Filippo Turati'   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Alzheimer's disease; Antidepressant drugs; Dementia; Depression

Indexed keywords

ANTIDEPRESSANT AGENT; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYMPTOM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS; COGNITION; COGNITION DISORDERS; DEPRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 42449114060     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000121334     Document Type: Article

References (44)

1. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC: Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000;157:708-714.
2. Migliorelli R, Teson A, Sabe L, Petracchi M, Leiguarda R, Starkstein SE: Prevalence and correlates of dysthymia and major depression among patients with Alzheimer's disease. Am J Psychiatry 1995;152:37-44.
3. Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, Smith GE, Geda YE, Cummings JL, Petersen RC, Sunderland T: A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am J Psychiatry 2003;160:857-866.
4. Lyketsos CG, Olin J: Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry 2002;52:243-252.
5. Lyketsos CG, Steele C, Baker L, Galik E, Kopunek S, Steinberg M, Warren A: Major and minor depression in Alzheimer's disease: prevalence and impact. J Neuropsychiatry Clin Neurosci 1997;9:556-561.
6. Milwain EJ, Nagy Z: Depressive symptoms increase the likelihood of cognitive impairment in elderly people with subclinical Alzheimer pathology. Dement Geriatr Cogn Disord 2005;19:46-50.
7. Powlishta KK, Storandt M, Mandernach TA, Hogan E, Grant EA, Morris JC: Absence of effect of depression on cognitive performance in early-stage Alzheimer disease. Arch Neurol 2004;61:1265-1268.
8. Shim YS, Yang DW: Depression as prognostic factor: 6 months follow-up in a geriatric institution. Arch Gerontol Geriatr 2006;43:277-283.
9. Janzing JG, Naarding P, Eling P: Depressive symptoms predict slow cognitive decline in mild dementia. Dement Geriatr Cogn Disord 2005;20:77-81.
10. Starkstein SE, Chemerinski E, Sabe L, Kuzis G, Petracca G, Teson A, Leiguarda R: Prospective longitudinal study of depression and anosognosia in Alzheimer's disease. Br J Psychiatry 1997;171:47-52.
11. Caltagirone C, Bianchetti A, Di Luca M, Mecocci P, Padovani A, Pirfo E, Scapicchio P, Senin U, Trabucchi M, Musicco M: Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics. Drugs Aging 2005;22(suppl 1):1-26.
12. Nyth AL, Gottfries CG: The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry 1990;157:894-901.
13. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, Baker AS, Sheppard JM, Frangakis C, Brandt J, Rabins PV: Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003;60:737-746.
14. Petracca GM, Chemerinski E, Starkstein SE: A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 2001;13:233-240.
15. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, Refsum HE, Ofsti E, Eriksson S, Syversen S: A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86:138-145.
16. Munro CA, Brandt J, Sheppard JM, Steele CD, Samus QM, Steinberg M, Rabins PV, Lyketsos CG: Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the depression in Alzheimer's disease study (DIADS). Am J Geriatr Psychiatry 2004;12:491-498.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
18. Folstein MF, Folstein SE, McHugh PR: 'Minimental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
19. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW: Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963;185:914-919.
20. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
21. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, Leirer VO: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17:37-49.
22. Cummings JL: The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48:S10-S16.
23. Parmelee PA, Thuras PD, Katz IR, Lawton MP: Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995;43:130-137.
24. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RW, Symon L: Cerebral blood flow in dementia. Arch Neurol 1975;32:632-637.
25. Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD: Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry 2002;10:129-141.
26. Vilalta-Franch J, Garre-Olmo J, Lopez-Pousa S, Turon-Estrada A, Lozano-Gallego M, Hernandez-Ferrandiz M, Pericot-Nierga I, Feijoo-Lorza R: Comparison of different clinical diagnostic criteria for depression in Alzheimer disease. Am J Geriatr Psychiatry 2006;14:589-597.
27. Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, Reynolds CF III, Rovner BW, Steffens DC, Tariot PN, Lebowitz BD: Provisional diagnostic criteria for depression of Alzheimer disease. Am J Geriatr Psychiatry 2002;10:125-128.
28. Bungener C, Jouvent R, Derouesne C: Affective disturbances in Alzheimer's disease. J Am Geriatr Soc 1996;44:1066-1071.
29. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA: Cornell Scale for Depression in Dementia. Biol Psychiatry 1988;23:271-284.
30. McGivney SA, Mulvihill M, Taylor B: Validating the GDS depression screen in the nursing home. J Am Geriatr Soc 1994;42:490-492.
31. Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;CD005593.
32. Wolstenholme J, Fenn P, Gray A, Keene J, Jacoby R, Hope T: Estimating the relationship between disease progression and cost of care in dementia. Br J Psychiatry 2002;181:36-42.
33. Butters MA, Becker JT, Nebes RD, Zmuda MD, Mulsant BH, Pollock BG, Reynolds CF III: Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry 2000;157:1949-1954.
34. Roth M, Mountjoy CQ, Amrein R: Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry 1996;168:149-157.
35. Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein SE: A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1996;8:270-275.
36. Lai MK, Tsang SW, Alder JT, Keene J, Hope T, Esiri MM, Francis PT, Chen CP: Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. Psychopharmacology (Berl) 2005;179:673-677.
37. Bentue-Ferrer D, Tribut O, Polard E, Allain H: Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 2003;17:947-963.
38. Dringenberg HC, Zalan RM: Serotonin-dependent maintenance of spatial performance and electroencephalography activation after cholinergic blockade: effects of serotonergic receptor antagonists. Brain Res 1999;837:242-253.
39. Dringenberg HC, Diavolitsis P: Electroencephalographic activation by fluoxetine in rats: role of 5-HT(1A) receptors and enhancement of concurrent acetylcholinesterase inhibitor treatment. Neuropharmacology 2002;42:154-161.
40. Bragin V, Chemodanova M, Dzhafarova N, Bragin I, Czerniawski JL, Aliev G: Integrated treatment approach improves cognitive function in demented and clinically depressed patients. Am J Alzheimers Dis Other Demen 2005;20:21-26.
41. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D: Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006;63:530-538.
42. Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M, Perl DP, Purohit DP, Gorman JM, Haroutunian V: Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 2006;63:161-167.
43. Mossello E, Boncinelli M: Mini-Mental State Examination: a 30-year story. Aging Clin Exp Res 2006;18:271-273.
44. Tombaugh TN, McIntyre NJ: The mini-mental state examination: a comprehensive review. J Am Geriatr Soc 1992;40:922-935.